This study examined the baseline characteristics, racial/ethnic differences, and geographic differences among participants in the Secondary Prevention of Small Subcortical Strokes (SPS3) study. The SPS3 trial enrolled patients who experienced a symptomatic small subcortical stroke (lacunar stroke) within the previous 6 months and an eligible lesion on detected on magnetic resonance imaging. The patients were randomized, in a factorial design, to antiplatelet therapy (aspirin 325 mg daily plus clopidogrel 75 mg daily vs aspirin 325 mg daily plus placebo) and to one of two levels of systolic blood pressure targets (''intensive'' [,130 mmHg] or ). A total of 3020 participants were recruited from 81 clinical sites in 8 countries. In this cohort, the mean age was 63 years, 63% were men, 75% had a history of hypertension, and 37% had diabetes. The racial distribution was 51% white, 30% Hispanic, and 16% black. Compared with white subjects, black subjects were younger (mean age, 58 years vs 64 years; P ,.001) and had a higher prevalence of hypertension (87% vs 70%; P ,.001). The prevalence of diabetes was higher in the Hispanic and black subjects compared with the white subjects (42% and 40% vs 32%; both P ,.001).
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Small subcortical stroke (S3), also known as lacunar stroke, is a common stroke subtype, comprising 25% of reported ischemic strokes. 1 Although the short-term prognosis is more favorable in S3 than in other stroke subtypes, stroke recurrence ranges between 4% and 11% per year, and S3 is the most common stroke subtype associated with vascular cognitive impairment and vascular dementia. 2, 3 S3s are particularly frequent in Hispanic Americans, 4, 5 who may have a worse prognosis than the general population.
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The rationale for the Secondary Prevention of Small Subcortical Strokes (SPS3) study has been published in detail elsewhere. 7 In brief, an optimal antiplatelet strategy is lacking for secondary stroke prevention in patients with S3, due mainly to small vessel disease. The efficacy of aspirin and clopidogrel compared with aspirin alone for prevention of vascular events has been demonstrated [8] [9] [10] and has prompted evaluation in individuals with S3. Hypertension is a highly prevalent and significant risk factor for stroke in general and particularly for S3. 11, 12 Treatment of hypertension also has been associated with reduced cognitive decline. 13 Relatively little is known about the optimal target levels of blood pressure control for secondary stroke prevention in well-defined ischemic stroke subtypes, however. The SPS3 study was designed to rigorously test in parallel whether combination antiplatelet therapy comprising aspirin plus clopidogrel is superior to aspirin alone, and whether ''intensive'' blood pressure lowering is superior to ''usual'' blood pressure management, for reducing stroke recurrence (the primary endpoint), cognitive decline, and major vascular events. A secondary aim was to compare absolute differences in the benefit of these interventions on outcomes between Hispanic and nonHispanic white participants. We describe the demographic and clinical features of participants included in SPS3, focusing on differences according to race/ethnicity.
Methods

Design and Sample
SPS3 is a randomized, multicenter clinical trial sponsored by the National Institutes of Health, National Institute of Neurological Disorders and Stroke. Details of the study design have been published elsewhere 7 ; we summarize pertinent aspects. Eligibility criteria were clinical lacunar stroke syndrome or subcortical transient ischemic attack (TIA) in the 6 months before enrollment with confirmation by magnetic resonance imaging, no clinical or radiological evidence of cortical involvement, and no surgically amenable ipsilateral carotid artery disease or major-risk cardioembolic sources. Patients with subcortical TIAs required confirmation by MRI diffusion-weighted imaging (DWI) to be eligible. Exclusion criteria included radiological or clinical evidence of a previous cortical/retinal stroke/TIA, previous intracranial hemorrhage or hemorrhagic infarct, disabling stroke, impaired renal function, high risk of bleeding, or cognitive impairment. Patients were randomized in a 2 3 2 factorial design to one of two interventions, antiplatelet therapy with aspirin 325 mg/day or with aspirin 325 mg/day plus clopidogrel 75 mg/day (double-blind, placebo-controlled), and to one of two target levels of systolic blood pressure control, or ''intensive'' (,130 mmHg). The SPS3 study was approved by the Institutional Review Boards of all participating centers, and all patients provided written informed consent.
Procedures
Medical history before the qualifying stroke was collected from all participants at study entry. A history of hypertension was defined by at least one of the following criteria: (1) consistent recording of hypertension in medical records for $1 year, (2) medical record or self-reported use of at least one antihypertensive medication and/or adjustment to achieve blood pressure control, and (3) medical record of blood pressure elevation sustained for $3 months. A history of diabetes was defined as chronic elevation of fasting serum glucose .120 mg/dL or chronic requirement for hypoglycemic medication. Appendix 1 provides detailed study definitions for all vascular risk factors.
Before entry, patients were screened for cognitive dysfunction with the Folstein Mini Mental Status Examination (MMSE), 14 and a detailed cognitive assessment was performed. Only patients with an MMSE score not more than 2 standard deviations below the mean for age and education were entered into the trial. All patients underwent a standardized neurologic exam, 15 and functional recovery was assessed using the modified Rankin Scale (mRS), 16, 17 Barthel Index, 18 and Edinburgh Stroke Outcome Questionnaire. 19 
Classification of Race/Ethnicity
Race and ethnicity were determined primarily by selfreport, using the 2 US Census 2000 questions regarding race and Hispanic/Latino ethnicity. Based on a recommended combined format, the following categories were used to collect the racial/ethnic data: American Indian or Alaskan Native; Asian or Pacific Islander; black, not of Hispanic origin; Hispanic; and white, not of Hispanic origin. 20 The first 2 categories (and ''other race'' category) were collapsed because of very small numbers. All participants declaring themselves as Hispanic were classified as Hispanic, including participants from Latin America. All participants declaring themselves as white (and not Hispanic) were classified as non-Hispanic white (hereinafter referred to as white). Participants from Spain were included in this category. 21 Similarly, participants self-reporting their race as black or African American (and not Hispanic) were classified as non-Hispanic black (hereinafter referred to as black). Twenty-two participants (18 from North America and 4 from Latin America) self-identified as Hispanic and black and were classified as black.
Data Analyses
Data are presented as frequency (percentage) for categorical variables and as mean (standard deviation)/median (interquartile range) for continuous variables. Our analyses examined differences by ethnic/racial subgroups. Specific comparisons were made between Hispanic and white subgroups and black and white subgroups using the c 2 test, Student t test, and Wilcoxon rank-sum test as appropriate. All tests of significance were 2-sided. Significant differences at P ,.01 and P ,.001 are noted. Differences were also examined by geographic region. Although Mexico is part of both North America and Latin America, for comparisons made here, Mexico was included with Latin America. SAS version 9.2 (SAS Institute, Cary, NC) was used for all statistical analyses.
Results
A total of 3020 patients with a recent symptomatic S3 were recruited from 81 clinical centers in the United States, Canada, Mexico, Ecuador, Peru, Chile, Argentina, and Spain (Fig 1) between May 2003 and April 2011 and randomized into one of the 4 treatment groups. Detailed information on randomizations by clinical site is provided in Appendix 2. Average time between the qualifying stroke and study randomization was 76 6 47 days. Demographic and clinical characteristics for the cohort overall and by race/ethnic subgroup are presented in Tables 1 and 2 . In what follows, we highlight findings from the overall cohort and differences by race/ethnicity.
SPS3 Cohort
The mean patient age was 63 6 11 years, and 63% of the cohort was male ( Table 1 ). The most prevalent risk factors were hypertension (75%), hyperlipidemia (49%), and diabetes (37%). Thirty percent reported a parental history of stroke, 10% reported a previous stroke, and 5% reported a TIA. Approximately one-third of the patients reported taking an antithrombotic medication regularly in the 7 days before the qualifying event, with 28% reporting aspirin specifically.
In the vast majority of patients (97%), the qualifying event was a stroke, with pure motor hemiparesis the most common presenting syndrome (33%), followed by sensorimotor stroke (31%). Only 6% of the cohort presented with a dysarthria clumsy-hand syndrome. Site investigators determined the localization of lesions based on clinical and radiological data; they localized 24% of lesions to the corona radiata/centrum semiovale, 28% to the basal ganglia/internal capsule, 22% to the thalamus and 26% to the brainstem or cerebellum (data not shown). Table 2 provides information on selected clinical characteristics at the time of trial entry (approximately 2.5 months after stroke). Two-thirds of the overall cohort demonstrated good functional recovery from the . The mean systolic and diastolic blood pressures at baseline were 143 6 19 mmHg and 78 6 11 mmHg, respectively. A high percentage of patients reported taking antihypertensive medications (85%) and lipid-lowering medications (73%) at trial entry. Of note, mean serum glucose level was elevated in the overall cohort (125 6 55.1 mg/dL), and mean glycosylated hemoglobin was elevated in the subgroup of patients with diabetes (8.3% 6 2.2%).
Racial/Ethnic Comparisons
The cohort was 51% non-Hispanic white, 30% Hispanic, and 16% non-Hispanic black (Fig 2) . Seventy-four participants (3%) self-reported race as American Indian/Alaskan Native, Asian/Pacific Islander or ''other.'' Because of the small numbers and heterogeneity of the ''other'' group, data for these patients are not presented.
The average age of black participants at trial entry was 58 years, significantly younger than the average age of 64 years for both Hispanic and white participants (both P ,.001) ( Table 1 ). There were significant differences by race/ethnicity in lifestyle behaviors, including smoking status, alcohol use, and regular exercise. Compared with whites, both Hispanic and black participants were significantly more likely to have a history (before the qualifying stroke) of hypertension (70% vs 76% and 87%, respectively; both P ,.001) and diabetes (32% vs 42% and 40%, respectively; both P ,.001). In contrast, whites were significantly more likely than Hispanics to have a history of ischemic heart disease (13% vs 6%; P ,.001). Blacks were significantly more likely than whites to report a previous symptomatic S3 (13% vs 9%; P ,.01), but significantly less likely to report regular aspirin in the 7 days before the qualifying event (26% vs 33%; P ,.01). Hispanics also were also less likely than whites to report regular aspirin use (21% vs 33%; P ,.001).
An mRS score of 0-1 was recorded at study enrollment for 71% of white participants (Table 2 ). In contrast, this same level of recovery was demonstrated by only 65% of Hispanic participants and by only 55% of black participants (both P ,.001). Compared with whites (141 6 17.2 mm Hg), average systolic blood pressure was significantly higher in Hispanics and blacks (144 6 20 mm Hg and 147 6 19.9 mm Hg, respectively; both P ,.001). Blacks yBarthel Index ranges from 0 to 100, with higher scores indicating better function; mRS score ranges from 0 to 6, with lower scores indicating better function.
zSignificantly different from the non-Hispanic white population at P #.001. xSignificantly different from the non-Hispanic white population at P #.01.
SPS3: CLINICAL FEATURES AND RACIAL/ETHNIC DIFFERENCES
were more likely than whites to be using antihypertensive medication at study entry (92% vs 83%; P ,.001), and racial/ethnic differences were seen by antihypertensive medication class. Hispanics were less likely than whites to be taking lipid-lowering medications at study entry (65% vs 76%; P ,.001). Mean glycosylated hemoglobin was higher in whites than in both Hispanics and blacks (7.7% 6 2.28.6% 6 2.1 and 9.1% 6 2.3 respectively; both P ,.001).
Geographic Comparisons
Of the 3020 participants in SPS3, 65% were from North America (United States and Canada), 23% were from Latin America (Mexico, Ecuador, Peru, Chile, and Argentina), and 12% were from Spain (Table 3) . Although the majority of Hispanic participants were from Latin American sites, participants from North America showed diversity, with 40% of participants classified as race/ethnicity other than non-Hispanic white. Participants from North America were significantly younger at stroke onset compared with those from Latin America and Spain (mean age, 62 vs 66 and 65 years, respectively; P ,.01) and less likely to be male (male preponderance, 60% vs 65% and 75%, respectively; P ,.01). Tobacco smoking at the time of qualifying stroke was much more frequent among Spanish participants than among North American and Latin American participants (32% vs 22% and 9%, respectively; P ,.01). There were significant differences in vascular risk factors by geographic region. Participants from Spain were significantly less likely to report a history of hypertension compared with those from North America and Latin America (60% vs 78% and 76%, respectively; P ,.01) and entry systolic blood pressure was 4 mmHg lower in Spanish participants compared with North American participants (P ,.01). Participants from North America were significantly more likely than those fron Latin American and Spain to report a history of hyperlipidemia and ischemic heart disease (P ,.01). Participants from North America were significantly more likely than those from Latin America and Spain to report regular aspirin use in the 7 days before the qualifying stroke (37% vs 20% and 21%, respectively; P ,.01). There were significant differences by geographic region in the use of both antihypertensive and lipid-lowering medications at trial entry (P ,.01). There also were significant differences in mean BMI by geographic region, with the highest mean BMI found in North America (30 6 7.5), followed by Spain (28 6 4) and then Latin America (27 6 5) .
Discussion
Our analysis of this large, racially and geographically diverse cohort of patients with recent subcortical ischemic stroke has identified significant differences in age, sex, and vascular risk factors among the white, black, and Hispanics participants. These differences are likely to impact the prognosis for recurrent stroke and cognitive impairment and perhaps the response to blood pressure control and antiplatelet therapies. For example, blood pressure control may offer a greater relative benefit to blacks (who have the highest prevalence of hypertension) compared with Hispanics (who have the highest prevalence of diabetes). These hypotheses will be addressed using outcome data involving stroke, cognition and death accumulated during the anticipated 4-year mean follow-up of this cohort.
The differences in stroke risk factors among the white, black, and Hispanic participants reported here are consistent with findings from previous studies and may reflect racial/ethnic-based disparities in stroke care. 21 Of particular note is the 6-year difference in age of onset of stroke, with an average age of 58 6 9.5 years for black participants, compared with 64 6 10.8 years for whites and 64 6 10.7 years for Hispanics. This younger age, coupled with the level of functional recovery at entry to trial, with only 55% of blacks reporting normal or nearnormal status compared with 65% for Hispanics and 71% for whites, underscores the important effect of stroke for blacks on disability-free years. Furthermore, the black participants were more likely to have a history of previous subcortical stroke, but yet less likely to report regular aspirin use in the 7 days before the index stroke. Hispanic participants were similarly less likely to report regular use of antiplatelet medication before the index stroke. Morgenstern et al 22 reported that only two-thirds of Mexican American participants in the Brain Attack Surveillance in Corpus Christi (BASIC) project were taking antiplatelet medication for secondary stroke prevention. Consistent with previous reports, black participants were significantly more likely to be hypertensive, with a higher mean blood pressure at trial entry. [23] [24] [25] Similar to findings from the BASIC project, 26 Hispanics had a significantly higher prevalence of diabetes compared with whites (42% vs 32%), whereas whites had a significantly higher prevalence of ischemic heart disease compared with Hispanics (13% vs 6%). The lower prevalence of diabetes in Latin American participants compared with Hispanic participants overall (38% vs 42%) suggests that the higher rate of diabetes in Hispanics may be driven by a high prevalence in North American Hispanics. SPS3 was designed to address several important clinical and scientific questions relevant to a common stroke subtype, lacunar infarct. The inclusion criteria were stringent to ensure that small-vessel disease was the most likely underlying mechanism of the lacunar infarct. The exclusion criteria were carefully considered to enhance the generalizability of the trial findings to the millions of patients with this common vascular disorder. Nonetheless, clinical trials suffer from problems with external validity, and SPS3 is no exception. To examine whether the SPS3 sample is representative of the larger population of patients with lacunar stroke, we compared baseline characteristics from SPS3 participants with available characteristics from published series of both hospital and population-based patients with lacunar stroke, selected because patients in the series underwent neuroimaging (Table 4) . These samples are diverse in terms of country of origin as well as study period, with publications dating between 1989 and 2011. Abbreviations: DM, diabetes mellitus; HPL, hyperlipidemia; HTN, hypertension; IHD, ischemic heart disease; NR, not reported; PVD, peripheral vascular disease. Data are presented as mean 6 SD or percentage. *Six patients (0.1%) were unable to undergo MRI related to medical reasons and were entered into the study with CT scan that demonstrated the corresponding lesion.
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The average age at trial entry for SPS3 participants was 63 years, falling within the range seen in the present series and consistent with reports of a younger average age of persons with lacunar stroke compared with those with other stroke subtypes. 27, 28 There is considerable variability in the prevalence of vascular risk factors across the reported series. For example, the prevalence of hypertension ranges from a low of 41% in the Finnish cohort 29 to a high of 88% in the German cohort, 30 with the majority of studies reporting at least 60% prevalence and SPS3 reporting 75%. SPS3 is among the studies reporting the highest prevalence of diabetes. Differences in prevalence may be related to inconsistencies in how the vascular risk factors were defined, as well as in the sources of participants. SPS3 is the only clinical trial of these series. Despite the strict criteria imposed on patient inclusion in a clinical trial, the baseline characteristics of the SPS3 cohort fall within the ranges reported in these series, which suggests that the data from SPS3 are applicable to the overall population of patients with lacunar stroke. The lack of generally accepted and consistently applied definitions of ethnicity across studies 21 posed a challenge in the present study, particularly with the inclusion of sites from Spain and Latin America. We made several assumptions in our classification scheme, including that the participants from South America were Hispanic and that the participants from Spain were not Hispanic. Even within each racial/ethnic group, there is considerable heterogeneity relative to culture and environment, which limits conclusions regarding any differences between racial/ethnic groups. Furthermore, our results highlighting racial/ethnic differences are presented for the purpose of fully describing the clinical features of the SPS3 cohort; because our data are unadjusted and cross-sectional, we are unable to draw conclusions regarding the reasons for differences by race/ethnicity. These unadjusted findings do emphasize the greater prevalence of stroke risk factors in blacks and Hispanics, as well as the greater impact on functional recovery at approximately 3 months after the index stroke.
In conclusion, our comparison of baseline characteristics in the SPS3 cohort and other published lacunar stroke series demonstrates that the SPS3 cohort is representative of patients with lacunar stroke in general. This finding supports the generalizability of the SPS3 trial results to the millions of patients around the world with this common disorder. In light of its multiracial cohort, the SPS3 results should further the understanding of racial/ethnic differences in stroke risk and prevention.
